IP10 C8

Drug Profile

IP10 C8

Alternative Names: IP10C8

Latest Information Update: 12 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IMTM GmbH
  • Class Anti-inflammatories; Antipsoriatics; Small molecules
  • Mechanism of Action CD13 antigen inhibitors; CD26 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acne; Psoriasis

Most Recent Events

  • 12 Aug 2015 No recent reports on development identified - Phase-I for Acne in Germany (Topical)
  • 12 Aug 2015 No recent reports on development identified - Phase-II for Psoriasis in Switzerland (Topical)
  • 07 Apr 2011 Phase II development in Psoriasis and clinical development in Acne is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top